Navigating Biosimilar Reimbursement: Key Challenges and Steps to Success
McKesson’s experts address the most important clinical, operational, and economical obstacles to overcome on the path to reimbursement.
Three Biosimilar Barriers in Community Clinic
An in depth look at the primary concerns of physicians when implementing biosimilars in their oncology and rheumatology practices.
From Clinical Use to Reimbursement
Dr. Robert Rifkin, medical director of biosimilars for McKesson, gives an update on biosimilar education and reimbursement.
Perfect Storm for Biosimilar Marketing
Dr. Robert Rifkin discusses the "perfect storm" for biosimilar marketing in a recent OncLive article.
Biosimilars: A Recent Review of Clinical Outcomes
A review of 14,000 individuals transitioned from a reference biologic medication to a biosimilar examines patient safety and treatment efficacy.
Overcoming Physician Barriers to Biosimilar Adoption in Clinics (PDF, 228 KB)
Omar Hafez shares how biopharmaceutical companies can learn how to overcome the clinical, operational, and economic barriers to biosimilar adoption.